Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Conditions
Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia · Refractory Small Lymphocytic Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Contact: Principal Investigator (Benjamin M. Heyman)City of Hope at Irvine Lennar, Irvine, California, United States
Contact: Principal Investigator (Benjamin M. Heyman)University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Contact: Principal Investigator (Sheila Firoozan)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Jennifer R. Brown)UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Deborah M. Stephens)Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Kerry A. Rogers)University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (John C. Byrd)Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Contact: Principal Investigator (Margaret K. Baron)
Study leads
Jennifer R Brown
Principal Investigator
Dana-Farber - Harvard Cancer Center LAO